The invention relates to mammal prolactin (PRL) variants having a mutation or set of mutations within the 14 N-terminal amino acids thereby preventing the formation of a disulfide bridge between Cys4 and Cys11 and, a sterically hindering mutation or set of mutations within binding site 2 of PRL. These variants are useful as antagonists of mammal prolactin receptors (PRLR), more particularly of human prolactin receptor (hPRLR).
申请公布号
WO03057729(A2)
申请公布日期
2003.07.17
申请号
WO2003EP00448
申请日期
2003.01.08
申请人
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM;GOFFIN, VINCENT;BERNICHTEIN, SOPHIE;KELLY, PAUL, A.
发明人
GOFFIN, VINCENT;BERNICHTEIN, SOPHIE;KELLY, PAUL, A.